NanoViricides Inc (NYSEAMERICAN:NNVC) was the recipient of a significant increase in short interest in the month of March. As of March 29th, there was short interest totalling 184,053 shares, an increase of 135.3% from the March 15th total of 78,226 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average daily trading volume, of 281,738 shares, the days-to-cover ratio is currently 0.7 days.

NYSEAMERICAN NNVC opened at $0.27 on Wednesday. NanoViricides has a 12-month low of $0.20 and a 12-month high of $0.86.

NanoViricides (NYSEAMERICAN:NNVC) last announced its quarterly earnings results on Tuesday, February 19th. The company reported ($0.03) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.03).

WARNING: This report was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.watchlistnews.com/nanoviricides-inc-nnvc-sees-large-increase-in-short-interest/2951765.html.

NanoViricides Company Profile

NanoViricides, Inc, a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS.

See Also: What is Put Option Volume?

Receive News & Ratings for NanoViricides Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoViricides and related companies with MarketBeat.com's FREE daily email newsletter.